Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results

@article{Consortium2020RepurposedAD,
  title={Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results},
  author={WHO Solidarity Trial Consortium and Hongchao Pan and Richard Peto and Quarraisha Abdool Karim and Marissa M Alejandria and Ana Maria Henao Restrepo and C{\'e}sar Hern{\'a}ndez Garc{\'i}a and Marie Paule Kieny and Reza Malekzadeh and Srinivas Murthy and Marie Pierre Pr{\'e}ziosi and Suresh Reddy and M. Roses and Vaseeharan Sathiyamoorthy and John-Arne R{\o}ttingen and Soumya Swaminathan},
  journal={medRxiv},
  year={2020}
}
BACKGROUND WHO expert groups recommended mortality trials in hospitalized COVID-19 of four re-purposed antiviral drugs. METHODS Study drugs were Remdesivir, Hydroxychloroquine, Lopinavir (fixed-dose combination with Ritonavir) and Interferon-{beta}1a (mainly subcutaneous; initially with Lopinavir, later not). COVID-19 inpatients were randomized equally between whichever study drugs were locally available and open control (up to 5 options: 4 active and local standard-of-care). The intent-to… 
Remdesivir Efficacy in COVID-19 Treatment: A Randomized Controlled Trial
TLDR
Remdesivir had a positive influence on length of hospital stay, but it had no mortality benefit in Egyptian patients with COVID-19, and its use, in addition to standard care including dexamethasone, should be considered, particularly in low- and middle-income countries when other effective options are scarce.
Covid-19: Remdesivir has little or no impact on survival, WHO trial shows
The largest trial to date of treatments repurposed for use in the covid-19 pandemic has shown that none of the four drugs studied produced any measurable benefit in mortality or disease course. This
Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial
TLDR
The results show that HCQ 400 mg twice a day for the first day followed by 200 mg once daily for the next 4 days was safe but not associated with reduction in viral clearance or symptom resolution among adults with COVID-19 in Uganda.
Remdesivir and Mortality in Patients with COVID-19.
TLDR
Treatment with RDV was associated with lower mortality compared to BSC, and these findings remain the same in the subgroup with baseline use of low-flow oxygen.
Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities
TLDR
The importance of the drug repurposing strategy in the context of COVID-19, including regulatory and ethical aspects, is highlighted, with a specific focus on novel pharmaceutical formulations and routes of administration.
The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroids
TLDR
Remdesivir was not associated with reduced risk of in-hospital mortality in patients with COVID-19 treated with steroids but potentially associated with decreased risk of AKI, and should be confirmed in prospective studies focusing on CO VID-19 patients treating with steroids.
EFFICACY AND SAFETY OF REMDESIVIR IN THE TREATMENT OF COVID 19: A RETROSPECTIVE STUDY
TLDR
Remdesivir use along with standard therapy had showed signicant improvement in terms of clinical, laboratory parameters and recovery in patients with moderate to severe Covid 19 infection.
Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period
TLDR
Results after 5 days of RDV therapy were comparable to those of clinical trials, which could be related to dexamethasone use and improved management of COVID-19.
Real-world outcomes of COVID-19 treatment with remdesivir in a Spanish hospital
TLDR
The percent mortality was lower in these patients than was observed in all patients with severe COVID-19 admitted to the authors' center, and despite receiving RDSV, 1 in 3 patients needed higher levels of oxygen support, the sole mortality-related factor.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 30 REFERENCES
Remdesivir for the Treatment of Covid-19 — Final Report
TLDR
The data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19
TLDR
In patients hospitalized with COVID-19, hydroxychloroquine was not associated with reductions in 28-day mortality but was associated with an increased length of hospital stay and increased risk of progressing to invasive mechanical ventilation or death.
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
TLDR
In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care, and future trials in patients withsevere illness may help to confirm or exclude the possibility of a treatment benefit.
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
TLDR
In patients with severe Covid-19 not requiring mechanical ventilation, a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia, the magnitude of benefit cannot be determined.
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  • Peter W Marion Jennifer L Louise Natalie Jonathan Adrian Horby Mafham Bell Linsell Staplin Emberson Palfree, P. Horby, M. Landray
  • Medicine
    The Lancet
  • 2020
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
TLDR
In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.
Interferon beta-1a for COVID-19: critical importance of the administration route
Type I interferons, especially IFN-beta, have been appointed as potential leading therapeutics to tackle severe COVID-19 and are currently being evaluated in REMAP-CAP and the WHO’s Solidarity Trial.
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
TLDR
Among patients with moderate COVID-19, those randomized to a 10-day course of remdesivir did not have a statistically significant difference in clinical status compared with standard care at 11 days after initiation of treatment, but the difference was of uncertain clinical importance.
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials
TLDR
It is found that there is no benefit of hydroxychloroquine or chloroquine on the survival of COVID-19 patients, and the confidence interval is compatible with increased mortality or negligibly reduced mortality.
...
1
2
3
...